| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Intrinsic Factor Blocking Antibody
MessageSendout, Mayo test code: IFBA
Test Code
LAB857
Alias/See Also
Anti Intrinsic Factor
IF Blocking
Type 1 Intrinsic Factor Antibody
Intrinsic Factor Blocking Antibody
IFBA
IF Blocking
Type 1 Intrinsic Factor Antibody
Intrinsic Factor Blocking Antibody
IFBA
CPT Codes
86340
Preferred Specimen
1.0 mL of serum from a gold serum gel tube
Patient Preparation
1. Patient should be fasting for 8 hours.
2. This test should not be performed on patients who have received a vitamin B12 injection or radiolabeled vitamin B12 injection within the previous 2 weeks.
Minimum Volume
0.5 mL
Other Acceptable Specimens
Red tube
Instructions
Centrifuge and aliquot serum into a plastic vial.
Transport Container
Plastic vial
Transport Temperature
Refrigerated
Specimen Stability
Refrigerated (preferred): 14 days
Frozen: 14 days
Frozen: 14 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Hemolysis: Mild OK; Gross reject
Lipemia: Mild OK; Gross OK
Lipemia: Mild OK; Gross OK
Methodology
Immunoenzymatic Assay
FDA Status
Approved
Setup Schedule
Monday through Friday
Report Available
1-3 days
Limitations
Patients who have received a vitamin B12 injection or radiolabeled vitamin B12 injection within the previous 2 weeks may have high serum vitamin B12 levels, which can interfere with this assay leading to falsely elevated results.
Some patients with other autoimmune diseases may have positive intrinsic factor blocking antibody (IFBA) assays without suffering from pernicious anemia (PA). This is reported particularly in patients with autoimmune thyroid disease or type I diabetes mellitus. In the validation of this assay, 24 individuals with these autoimmune endocrine diseases were tested and all were IFBA negative. However, 5 of 15 of patients with rheumatoid arthritis were IFBA positive during the validation of this assay. The literature suggests such individuals may, in fact, be at risk of later development of PA.
Since this is a competitive binding assay, the risk of heterophile antibody interference is low. During validation, 24 human antimouse antibody positive specimens and 25 specimens with other heterophile antibodies were tested and all were IFBA negative. However, if the clinical picture does not agree with the IFBA test result, the laboratory should be consulted for advice.
Some patients with other autoimmune diseases may have positive intrinsic factor blocking antibody (IFBA) assays without suffering from pernicious anemia (PA). This is reported particularly in patients with autoimmune thyroid disease or type I diabetes mellitus. In the validation of this assay, 24 individuals with these autoimmune endocrine diseases were tested and all were IFBA negative. However, 5 of 15 of patients with rheumatoid arthritis were IFBA positive during the validation of this assay. The literature suggests such individuals may, in fact, be at risk of later development of PA.
Since this is a competitive binding assay, the risk of heterophile antibody interference is low. During validation, 24 human antimouse antibody positive specimens and 25 specimens with other heterophile antibodies were tested and all were IFBA negative. However, if the clinical picture does not agree with the IFBA test result, the laboratory should be consulted for advice.
Reference Range
Included with report
Clinical Significance
Confirming the diagnosis of pernicious anemia
Performing Laboratory
Mayo Clinic Laboratories, Rochester, Minnesota
Additional Information
Intrinsic Factor Blocking Antibody, Serum
